Reference
European Medicines Agency. EMA concludes safety review of Uptravi. Internet Document : 7 Apr 2017. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2017/04/news_detail_002726.jsp&mid=WC0b01ac058004d5c1
Rights and permissions
About this article
Cite this article
EMA review: continue to use selexipag as prescribed. Reactions Weekly 1648, 2 (2017). https://doi.org/10.1007/s40278-017-28981-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-017-28981-5